The Experts below are selected from a list of 10398 Experts worldwide ranked by ideXlab platform
Sharon H Giordano - One of the best experts on this subject based on the ideXlab platform.
-
Male Breast Cancer precursor lesions analysis of the eortc 10085 tbcrc big nabcg international Male Breast Cancer program
Modern Pathology, 2017Co-Authors: Shusma C Doebar, Sharon H Giordano, John M S Bartlett, Leen Slaets, Fatima Cardoso, Konstantinos Tryfonidis, Nizet H Dijkstra, C P SchroderAbstract:In men, data regarding Breast Cancer carcinogenesis are limited. The aim of our study was to describe the presence of precursor lesions adjacent to invasive Male Breast Cancer, in order to increase our understanding of carcinogenesis in these patients. Central pathology review was performed for 1328 Male Breast Cancer patients, registered in the retrospective joint analysis of the International Male Breast Cancer Program, which included the presence and type of Breast Cancer precursor lesions. In a subset, invasive Breast Cancer was compared with the adjacent precursor lesion by immunohistochemistry (n=83) or targeted next generation sequencing (n=7). Additionally, we correlated the presence of ductal carcinoma in situ with outcome. A substantial proportion (46.2%) of patients with invasive Breast Cancer also had an adjacent precursor lesion, mainly ductal carcinoma in situ (97.9%). The presence of lobular carcinoma in situ and columnar cell-like lesions were very low (<1%). In the subset of invasive Breast Cancer cases with adjacent ductal carcinoma in situ (n=83), a complete concordance was observed between the estrogen receptor, progesterone receptor, and HER2 status of both components. Next generation sequencing on a subset of cases with invasive Breast Cancer and adjacent ductal carcinoma in situ (n=4) showed identical genomic aberrations, including PIK3CA, GATA3, TP53, and MAP2K4 mutations. Next generation sequencing on a subset of cases with invasive Breast Cancer and an adjacent columnar cell-like lesion showed genomic concordance in two out of three patients. A multivariate Cox model for survival showed a trend that the presence of ductal carcinoma in situ was associated with a better overall survival, in particular in the Luminal B HER2+ subgroup. In conclusion, ductal carcinoma in situ is the most commonly observed precursor lesion in Male Breast Cancer and its presence seems to be associated with a better outcome, in particular in Luminal B HER2+ cases. The rate of lobular carcinoma in situ and columnar cell-like lesions adjacent to Male Breast Cancer is very low, but our findings support the role of columnar cell-like lesions as a precursor of Male Breast Cancer.
-
Male Breast Cancer precursor lesions : Analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Modern pathology : an official journal of the United States and Canadian Academy of Pathology Inc, 2017Co-Authors: Shusma C Doebar, Sharon H Giordano, John M S Bartlett, Leen Slaets, Fatima Cardoso, Konstantinos Tryfonidis, Nizet H Dijkstra, C P Schroder, Christi J. Van Asperen, Barbro LinderholmAbstract:In men, data regarding Breast Cancer carcinogenesis are limited. The aim of our study was to describe the presence of precursor lesions adjacent to invasive Male Breast Cancer, in order to increase our understanding of carcinogenesis in these patients. Central pathology review was performed for 1328 Male Breast Cancer patients, registered in the retrospective joint analysis of the International Male Breast Cancer Program, which included the presence and type of Breast Cancer precursor lesions. In a subset, invasive Breast Cancer was compared with the adjacent precursor lesion by immunohistochemistry (n=83) or targeted next generation sequencing (n=7). Additionally, we correlated the presence of ductal carcinoma in situ with outcome. A substantial proportion (46.2%) of patients with invasive Breast Cancer also had an adjacent precursor lesion, mainly ductal carcinoma in situ (97.9%). The presence of lobular carcinoma in situ and columnar cell-like lesions were very low (
-
multidisciplinary meeting on Male Breast Cancer summary and research recommendations
Journal of Clinical Oncology, 2010Co-Authors: Larissa A Korde, Jo Anne Zujewski, Leah Kamin, Sharon H Giordano, Zeina Nahleh, Karen A. Gelmon, Susan M Domchek, John M S Bartlett, William F. Anderson, Jonas BerghAbstract:Male Breast Cancer is a rare disease, accounting for less than 1% of all Breast Cancer diagnoses worldwide. Most data on Male Breast Cancer comes from small single-institution studies, and because of the paucity of data, the optimal treatment for Male Breast Cancer is not known. This article summarizes a multidisciplinary international meeting on Male Breast Cancer, sponsored by the National Institutes of Health Office of Rare Diseases and the National Cancer Institute Divisions of Cancer Epidemiology and Genetics and Cancer Treatment and Diagnosis. The meeting included representatives from the fields of epidemiology, genetics, pathology and molecular biology, health services research, and clinical oncology and the advocacy community, with a comprehensive review of the data. Presentations focused on highlighting differences and similarities between Breast Cancer in Males and feMales. To enhance our understanding of Male Breast Cancer, international consortia are necessary. Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of Male Breast Cancer.
-
A Review of the Diagnosis and Management of Male Breast Cancer
The oncologist, 2005Co-Authors: Sharon H GiordanoAbstract:Male Breast Cancer is an uncommon disease although the incidence has increased over the past 25 years. As with many other rare "orphan" diseases, Male Breast Cancer is understudied. The rarity of the disease precludes prospective randomized clinical trials. In addition, few researchers and minimal funding have focused on Breast Cancer in men, but further work is clearly needed to better understand this disease. It shares many similarities with Breast Cancer in women; yet some clear differences have emerged. In this article, the latest information on the epidemiology, biology, and treatment of Male Breast Cancer is reviewed.
C P Schroder - One of the best experts on this subject based on the ideXlab platform.
-
Male Breast Cancer precursor lesions analysis of the eortc 10085 tbcrc big nabcg international Male Breast Cancer program
Modern Pathology, 2017Co-Authors: Shusma C Doebar, Sharon H Giordano, John M S Bartlett, Leen Slaets, Fatima Cardoso, Konstantinos Tryfonidis, Nizet H Dijkstra, C P SchroderAbstract:In men, data regarding Breast Cancer carcinogenesis are limited. The aim of our study was to describe the presence of precursor lesions adjacent to invasive Male Breast Cancer, in order to increase our understanding of carcinogenesis in these patients. Central pathology review was performed for 1328 Male Breast Cancer patients, registered in the retrospective joint analysis of the International Male Breast Cancer Program, which included the presence and type of Breast Cancer precursor lesions. In a subset, invasive Breast Cancer was compared with the adjacent precursor lesion by immunohistochemistry (n=83) or targeted next generation sequencing (n=7). Additionally, we correlated the presence of ductal carcinoma in situ with outcome. A substantial proportion (46.2%) of patients with invasive Breast Cancer also had an adjacent precursor lesion, mainly ductal carcinoma in situ (97.9%). The presence of lobular carcinoma in situ and columnar cell-like lesions were very low (<1%). In the subset of invasive Breast Cancer cases with adjacent ductal carcinoma in situ (n=83), a complete concordance was observed between the estrogen receptor, progesterone receptor, and HER2 status of both components. Next generation sequencing on a subset of cases with invasive Breast Cancer and adjacent ductal carcinoma in situ (n=4) showed identical genomic aberrations, including PIK3CA, GATA3, TP53, and MAP2K4 mutations. Next generation sequencing on a subset of cases with invasive Breast Cancer and an adjacent columnar cell-like lesion showed genomic concordance in two out of three patients. A multivariate Cox model for survival showed a trend that the presence of ductal carcinoma in situ was associated with a better overall survival, in particular in the Luminal B HER2+ subgroup. In conclusion, ductal carcinoma in situ is the most commonly observed precursor lesion in Male Breast Cancer and its presence seems to be associated with a better outcome, in particular in Luminal B HER2+ cases. The rate of lobular carcinoma in situ and columnar cell-like lesions adjacent to Male Breast Cancer is very low, but our findings support the role of columnar cell-like lesions as a precursor of Male Breast Cancer.
-
Male Breast Cancer precursor lesions : Analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Modern pathology : an official journal of the United States and Canadian Academy of Pathology Inc, 2017Co-Authors: Shusma C Doebar, Sharon H Giordano, John M S Bartlett, Leen Slaets, Fatima Cardoso, Konstantinos Tryfonidis, Nizet H Dijkstra, C P Schroder, Christi J. Van Asperen, Barbro LinderholmAbstract:In men, data regarding Breast Cancer carcinogenesis are limited. The aim of our study was to describe the presence of precursor lesions adjacent to invasive Male Breast Cancer, in order to increase our understanding of carcinogenesis in these patients. Central pathology review was performed for 1328 Male Breast Cancer patients, registered in the retrospective joint analysis of the International Male Breast Cancer Program, which included the presence and type of Breast Cancer precursor lesions. In a subset, invasive Breast Cancer was compared with the adjacent precursor lesion by immunohistochemistry (n=83) or targeted next generation sequencing (n=7). Additionally, we correlated the presence of ductal carcinoma in situ with outcome. A substantial proportion (46.2%) of patients with invasive Breast Cancer also had an adjacent precursor lesion, mainly ductal carcinoma in situ (97.9%). The presence of lobular carcinoma in situ and columnar cell-like lesions were very low (
John M S Bartlett - One of the best experts on this subject based on the ideXlab platform.
-
Male Breast Cancer precursor lesions analysis of the eortc 10085 tbcrc big nabcg international Male Breast Cancer program
Modern Pathology, 2017Co-Authors: Shusma C Doebar, Sharon H Giordano, John M S Bartlett, Leen Slaets, Fatima Cardoso, Konstantinos Tryfonidis, Nizet H Dijkstra, C P SchroderAbstract:In men, data regarding Breast Cancer carcinogenesis are limited. The aim of our study was to describe the presence of precursor lesions adjacent to invasive Male Breast Cancer, in order to increase our understanding of carcinogenesis in these patients. Central pathology review was performed for 1328 Male Breast Cancer patients, registered in the retrospective joint analysis of the International Male Breast Cancer Program, which included the presence and type of Breast Cancer precursor lesions. In a subset, invasive Breast Cancer was compared with the adjacent precursor lesion by immunohistochemistry (n=83) or targeted next generation sequencing (n=7). Additionally, we correlated the presence of ductal carcinoma in situ with outcome. A substantial proportion (46.2%) of patients with invasive Breast Cancer also had an adjacent precursor lesion, mainly ductal carcinoma in situ (97.9%). The presence of lobular carcinoma in situ and columnar cell-like lesions were very low (<1%). In the subset of invasive Breast Cancer cases with adjacent ductal carcinoma in situ (n=83), a complete concordance was observed between the estrogen receptor, progesterone receptor, and HER2 status of both components. Next generation sequencing on a subset of cases with invasive Breast Cancer and adjacent ductal carcinoma in situ (n=4) showed identical genomic aberrations, including PIK3CA, GATA3, TP53, and MAP2K4 mutations. Next generation sequencing on a subset of cases with invasive Breast Cancer and an adjacent columnar cell-like lesion showed genomic concordance in two out of three patients. A multivariate Cox model for survival showed a trend that the presence of ductal carcinoma in situ was associated with a better overall survival, in particular in the Luminal B HER2+ subgroup. In conclusion, ductal carcinoma in situ is the most commonly observed precursor lesion in Male Breast Cancer and its presence seems to be associated with a better outcome, in particular in Luminal B HER2+ cases. The rate of lobular carcinoma in situ and columnar cell-like lesions adjacent to Male Breast Cancer is very low, but our findings support the role of columnar cell-like lesions as a precursor of Male Breast Cancer.
-
Male Breast Cancer precursor lesions : Analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Modern pathology : an official journal of the United States and Canadian Academy of Pathology Inc, 2017Co-Authors: Shusma C Doebar, Sharon H Giordano, John M S Bartlett, Leen Slaets, Fatima Cardoso, Konstantinos Tryfonidis, Nizet H Dijkstra, C P Schroder, Christi J. Van Asperen, Barbro LinderholmAbstract:In men, data regarding Breast Cancer carcinogenesis are limited. The aim of our study was to describe the presence of precursor lesions adjacent to invasive Male Breast Cancer, in order to increase our understanding of carcinogenesis in these patients. Central pathology review was performed for 1328 Male Breast Cancer patients, registered in the retrospective joint analysis of the International Male Breast Cancer Program, which included the presence and type of Breast Cancer precursor lesions. In a subset, invasive Breast Cancer was compared with the adjacent precursor lesion by immunohistochemistry (n=83) or targeted next generation sequencing (n=7). Additionally, we correlated the presence of ductal carcinoma in situ with outcome. A substantial proportion (46.2%) of patients with invasive Breast Cancer also had an adjacent precursor lesion, mainly ductal carcinoma in situ (97.9%). The presence of lobular carcinoma in situ and columnar cell-like lesions were very low (
-
multidisciplinary meeting on Male Breast Cancer summary and research recommendations
Journal of Clinical Oncology, 2010Co-Authors: Larissa A Korde, Jo Anne Zujewski, Leah Kamin, Sharon H Giordano, Zeina Nahleh, Karen A. Gelmon, Susan M Domchek, John M S Bartlett, William F. Anderson, Jonas BerghAbstract:Male Breast Cancer is a rare disease, accounting for less than 1% of all Breast Cancer diagnoses worldwide. Most data on Male Breast Cancer comes from small single-institution studies, and because of the paucity of data, the optimal treatment for Male Breast Cancer is not known. This article summarizes a multidisciplinary international meeting on Male Breast Cancer, sponsored by the National Institutes of Health Office of Rare Diseases and the National Cancer Institute Divisions of Cancer Epidemiology and Genetics and Cancer Treatment and Diagnosis. The meeting included representatives from the fields of epidemiology, genetics, pathology and molecular biology, health services research, and clinical oncology and the advocacy community, with a comprehensive review of the data. Presentations focused on highlighting differences and similarities between Breast Cancer in Males and feMales. To enhance our understanding of Male Breast Cancer, international consortia are necessary. Therefore, the Breast International Group and North American Breast Cancer Group have joined efforts to develop an International Male Breast Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This international collaboration will also facilitate the future planning of clinical trials that can address essential questions in the treatment of Male Breast Cancer.
Sarkis Meterissian - One of the best experts on this subject based on the ideXlab platform.
-
Successful use of letrozole in Male Breast Cancer: a case report and review of hormonal therapy for Male Breast Cancer.
Journal of surgical oncology, 2005Co-Authors: Brent P. Zabolotny, Christian V. Zalai, Sarkis MeterissianAbstract:Male Breast Cancer is an uncommon occurrence. Treatment of Male Breast Cancer is typically extrapolated from data on the treatment of feMale Breast Cancer. Recently, aromatase inhibition has been proven as an effective therapy for feMale Breast Cancer, particularly in the setting of advanced Cancers. The efficacy of aromatase inhibitors in Males, however, has not been established. We report the successful treatment of a Male with locally advanced Breast Cancer using the aromatase inhibitor letrozole.
-
successful use of letrozole in Male Breast Cancer a case report and review of hormonal therapy for Male Breast Cancer
Journal of Surgical Oncology, 2005Co-Authors: Brent P. Zabolotny, Christian V. Zalai, Sarkis MeterissianAbstract:Male Breast Cancer is an uncommon occurrence. Treatment of Male Breast Cancer is typically extrapolated from data on the treatment of feMale Breast Cancer. Recently, aromatase inhibition has been proven as an effective therapy for feMale Breast Cancer, particularly in the setting of advanced Cancers. The efficacy of aromatase inhibitors in Males, however, has not been established. We report the successful treatment of a Male with locally advanced Breast Cancer using the aromatase inhibitor letrozole. J. Surg. Oncol. 2005;90:26–30. © 2005 Wiley-Liss, Inc.
Karin B Michels - One of the best experts on this subject based on the ideXlab platform.
-
physical activity and risk of Male Breast Cancer
Cancer Epidemiology Biomarkers & Prevention, 2015Co-Authors: Hannah Arem, Susan M Gapstur, Valerie Mccormack, Karin B Michels, Kenneth C. Johnson, Louise A Brinton, Steven C Moore, Laurel A Habel, Laurence N KolonelAbstract:The association between leisure-time physical activity (LTPA) and Male Breast Cancer risk is unclear. In the Male Breast Cancer Pooling Project, with 449 cases and 13,855 matched controls, we used logistic regression with study stratification to generate adjusted ORs and 95% confidence intervals (CI) for LTPA tertiles and Male Breast Cancer risk. Compared with low LTPA, medium and high LTPA were not associated with Male Breast Cancer risk (OR, 1.01; 95% CI, 0.79-1.29; 0.90, 0.69-1.18, respectively). In joint-effects analyses, compared with the referent of high body mass index (BMI; ≥25 kg/m(2))/low LTPA, neither medium nor high PA was associated with risk among high BMI men, but normal BMI men (<25 kg/m(2)) with low or medium LTPA were at a nonsignificant ∼16% reduced risk and those with high LTPA were at a 27% reduced risk (OR, 0.73; 95% CI, 0.50-1.07). Physical activity alone may not confer protection against Male Breast Cancer risk.
-
Physical Activity and Risk of Male Breast Cancer
Cancer epidemiology biomarkers & prevention : a publication of the American Association for Cancer Research cosponsored by the American Society of Pre, 2015Co-Authors: Hannah Arem, Susan M Gapstur, Valerie Mccormack, Karin B Michels, Kenneth C. Johnson, Louise A Brinton, Steven C Moore, Laurel A Habel, Laurence N Kolonel, Howard D. SessoAbstract:The association between leisure-time physical activity (LTPA) and Male Breast Cancer risk is unclear. In the Male Breast Cancer Pooling Project, with 449 cases and 13,855 matched controls, we used logistic regression with study stratification to generate adjusted ORs and 95% confidence intervals (CI) for LTPA tertiles and Male Breast Cancer risk. Compared with low LTPA, medium and high LTPA were not associated with Male Breast Cancer risk (OR, 1.01; 95% CI, 0.79-1.29; 0.90, 0.69-1.18, respectively). In joint-effects analyses, compared with the referent of high body mass index (BMI; ≥25 kg/m(2))/low LTPA, neither medium nor high PA was associated with risk among high BMI men, but normal BMI men (
-
tobacco and alcohol in relation to Male Breast Cancer an analysis of the Male Breast Cancer pooling project consortium
Cancer Epidemiology Biomarkers & Prevention, 2015Co-Authors: Michael B Cook, Pascal Guenel, Susan M Gapstur, John T Casagrande, Rosie Cooke, Karin B Michels, Stephen K. Van Den Eeden, Piet A. Van Den Brandt, Marianne EwertzAbstract:Background: The etiology of Male Breast Cancer is poorly understood, partly due to its relative rarity. Although tobacco and alcohol exposures are known carcinogens, their association with Male Breast Cancer risk remains ill-defined. Methods: The Male Breast Cancer Pooling Project consortium provided 2,378 cases and 51,959 controls for analysis from 10 case-control and 10 cohort studies. Individual participant data were harmonized and pooled. Unconditional logistic regression was used to estimate study design-specific (case-control/cohort) odds ratios (OR) and 95% confidence intervals (CI), which were then combined using fixed effects meta-analysis. Results: Cigarette smoking status, smoking pack-years, duration, intensity, and age at initiation were not associated with Male Breast Cancer risk. Relations with cigar and pipe smoking, tobacco chewing, and snuff use were also null. Recent alcohol consumption and average grams of alcohol consumed per day were also not associated with risk; only one sub-analysis of very high recent alcohol consumption (>60 grams/day) was tentatively associated with Male Breast Cancer (ORunexposed referent=1.29, 95%CI:0.97-1.71; OR>0-<7 g/day referent=1.36, 95%CI:1.04-1.77). Specific alcoholic beverage types were not associated with Male Breast Cancer. Relations were not altered when stratified by age or body mass index. Conclusions: In this analysis of the Male Breast Cancer Pooling Project we found little evidence that tobacco and alcohol exposures were associated with risk of Male Breast Cancer. Impact: Tobacco and alcohol do not appear to be carcinogenic for Male Breast Cancer. Future studies should aim to assess these exposures in relation to subtypes of Male Breast Cancer.
-
Tobacco and Alcohol in Relation to Male Breast Cancer: An Analysis of the Male Breast Cancer Pooling Project Consortium
Cancer Epidemiology Biomarkers & Prevention, 2014Co-Authors: Michael B Cook, Pascal Guenel, Susan M Gapstur, John T Casagrande, Rosie Cooke, Marianne Ewertz, Karin B Michels, Stephen K. Van Den Eeden, Piet A. Van Den Brandt, Roni T FalkAbstract:Background: The etiology of Male Breast Cancer is poorly understood, partly due to its relative rarity. Although tobacco and alcohol exposures are known carcinogens, their association with Male Breast Cancer risk remains ill-defined. Methods: The Male Breast Cancer Pooling Project consortium provided 2,378 cases and 51,959 controls for analysis from 10 case-control and 10 cohort studies. Individual participant data were harmonized and pooled. Unconditional logistic regression was used to estimate study design-specific (case-control/cohort) odds ratios (OR) and 95% confidence intervals (CI), which were then combined using fixed effects meta-analysis. Results: Cigarette smoking status, smoking pack-years, duration, intensity, and age at initiation were not associated with Male Breast Cancer risk. Relations with cigar and pipe smoking, tobacco chewing, and snuff use were also null. Recent alcohol consumption and average grams of alcohol consumed per day were also not associated with risk; only one sub-analysis of very high recent alcohol consumption (>60 grams/day) was tentatively associated with Male Breast Cancer (ORunexposed referent=1.29, 95%CI:0.97-1.71; OR>0-